Roche: results of trial for Covid-19 patients

(CercleFinance.com) - Regeneron Pharmaceuticals today announced the first data from an analysis of a Phase 1/2/3 uninterrupted trial of its investigational REGN-COV2 antibody cocktail, which showed that it reduces viral load and the time for symptom relief in outpatients with Covid-19.


REGN-COV2 has also shown positive trends in reducing medical visits. The ongoing randomised, double-blind trial is measuring the effect of adding REGN-COV2 to the usual standard of care compared to adding placebo to the standard of care.

This trial is part of a larger program that also includes studies of REGN-COV2 for the treatment of hospitalised patients and for the prevention of infection in people who have been exposed to Covid-19 patients.


Copyright (c) 2020 CercleFinance.com. All rights reserved.